Hillstream Biopharma Learn more We aim to improve the lives of patients with rare cancers

About Hillstream Biopharma Inc.

Hillstream BioPharma is a development stage company focused on rare cancers.  By harnessing a weakness in tumors to preferentially concentrate Hillstream’s proprietary QuatramerTM technology, we are developing targeted cancer therapies.  The Company is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors which encode inflammatory cytokines directly into the tumor’s genome.  We will work to improve the lives of patients as we rapidly move into the clinic to treat small cell lung cancer, soft-tissue sarcomas and other high unmet need rare cancers.

Our Pipeline

HSB-1216: an enhanced injectable suspension of a long-acting ferroptosis inducer for small cell lung cancer

HSB-114: tumor-guided TNF-a DNA via non-viral vector enhanced injectable for soft tissue sarcoma

HSB-720: novel IO agent delivering tumor-targeted IL-2 DNA to solid tumors

Subscribe to Receive Hillstream Biopharma News and Updates By Email